PDCD1 and esophageal squamous cell carcinoma: Camrelizumab (SHR-1210), a humanized PD-1 monoclonal antibody, has been approved either alone or in combination by the National Drug Administration (NMPA) in China for the treatment of advanced or metastatic esophageal squamous cell cancer (ESCC).